SAiGENCI Cancer Research
SAiGENCI Cancer Research
100% of your gift will support leading-edge cancer research, which will lead to better outcomes for patients with cancer, and their families.
Support our research
Give now before 30 June and your donation will be matched.
For every dollar you give, $2 will go to supporting leading-edge cancer research.
Linda's story
Linda was 28-weeks pregnant with her second son when she noticed a small lump in her breast.
About SAiGENCI
SAiGENCI Director, Professor Christopher Sweeney and Associate Professor Luciano Martelotto with the centre's state-of-the-art equipment. Picture: Russell Millard/The Advertiser
SAiGENCI is an independent cancer-focused medical research institute located in South Australia; focusing on cancer research and clinical trials, which will include new cutting-edge technologies in immunotherapies and genomics.
Featured projects
Improving survivorship for children with brain cancer
Brain cancer is the most common solid tumour and most lethal type of cancer in Australian children. Furthermore, those who survive often experience debilitating longer-term effects, including a large percentage who are not able to achieve independence as adults.
Unlocking the mysteries of prostate cancer
The SAiGENCI team is creating a comprehensive data repository and applying machine learning to uncover revolutionary insights for prostate cancer treatment and prevention.
Give now
Linda with her family just weeks before receiving her diagnosis
Please help our researchers so families like Linda’s don’t have to go through the life-changing trauma of cancer.
It is devastating. I plea for research, and for a future where no woman faces a darkness like this. We are literally dying while we wait for new research and treatments.Linda
We need your support today.
Change lives
Jed's story
Jed was 17 and in year 12 when he was diagnosed with an aggressive brain tumour – changing his life in an instant.
Nick’s story
“Why me?” were some of Nick’s first thoughts when he was diagnosed with stage 1 prostate cancer at 45.